Astex (ASTX) Says FDA Committee Won't Support Dacogen Benefit/Risk Profile; Stock to Resume at 2:05pm ET
Tweet
Share
E-mailGet Alerts ASTX Hot Sheet
Join SI Premium – FREE
Shares of Astex Pharma (Nasdaq: ASTX) are set to resume trading at 2:05pm ET following news the FDA's Oncologic Drugs Advisory Committee voted not to support the current Dacogen profile.
Data in partner Eisai’s sNDA for Dacogen for Injection did not support a favorable benefit-risk profile for the treatment of acute myeloid leukemia (AML) in adults 65 years of age or older who are not considered candidates for induction therapy.
Data in partner Eisai’s sNDA for Dacogen for Injection did not support a favorable benefit-risk profile for the treatment of acute myeloid leukemia (AML) in adults 65 years of age or older who are not considered candidates for induction therapy.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
- Kimbell Royalty closes $221.2M mineral rights acquisition
Create E-mail Alert Related Categories
Corporate News, FDA, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
